Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3162304 46 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Circulating prolactin and breast cancer risk among pre- and
postmenopausal women in the EPIC cohort
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Experimental and epidemiological evidence suggests that prolactin might
play a role in the etiology of breast cancer. We analyzed the
relationship of prediagnostic circulating prolactin levels with the risk
of breast cancer by menopausal status, use of postmenopausal hormone
replacement therapy (HRT) at blood donation, and by estrogen and
progesterone receptor status of the breast tumors.
Conditional logistic regression was used to analyze the data from a
case-control study nested within the prospective European EPIC cohort,
including 2250 invasive breast cancer and their matched control
subjects.
Statistically significant heterogeneity in the association of prolactin
levels with breast cancer risk between women who were either pre- or
postmenopausal at the time of blood donation was observed (P-het =
0.04). Higher serum levels of prolactin were associated with significant
increase in the risk of breast cancer among postmenopausal women [odds
ratio (OR)(Q4-Q1) = 1.29 (95% confidence interval, CI, 1.05-1.58),
P-trend = 0.09]; however, this increase in risk seemed to be confined to
women who used postmenopausal HRT at blood donation [ORQ4-Q1 = 1.45
(95% CI 1.08-1.95), P-trend = 0.01], whereas no statistically
significant association was found for the non-users of HRT [ORQ4-Q1 =
1.11 (95%CI 0.83-1.49), P-trend = 0.80] (P-het = 0.08). Among
premenopausal women, a statistically non-significant inverse association
was observed [ORQ4-Q1 = 0.70 (95% CI 0.48-1.03), P-trend = 0.16].
There was no heterogeneity in the prolactin-breast cancer association by
hormone receptor status of the tumor.
Our study indicates that higher circulating levels of prolactin among
the postmenopausal HRT users at baseline may be associated with
increased breast cancer risk.
Έτος δημοσίευσης:
2014
Συγγραφείς:
Tikk, K.
Sookthai, D.
Johnson, T.
Rinaldi, S.
Romieu, I.
and Tjonneland, A.
Olsen, A.
Overvad, K.
Clavel-Chapelon, F.
and Baglietto, L.
Boeing, H.
Trichopoulou, A.
Lagiou, P. and
Trichopoulos, D.
Palli, D.
Pala, V.
Tumino, R.
Rosso, S.
and Panico, S.
Agudo, A.
Menendez, V.
Sanchez, M. -J. and
Amiano, P.
Huerta Castano, J. M.
Ardanaz, E. and
Bueno-de-Mesquita, H. B.
Monninkhof, E.
Onland-Moret, C. and
Andersson, A.
Sund, M.
Weiderpass, E.
Khaw, K. -T.
Key,
T. J.
Travis, R. C.
Gunter, M. J.
Riboli, E.
Dossus, L.
and Kaaks, R.
Περιοδικό:
Annals of Oncology
Εκδότης:
Oxford University Press
Τόμος:
25
Αριθμός / τεύχος:
7
Σελίδες:
1422-1428
Λέξεις-κλειδιά:
breast cancer; prolactin levels; hormone replacement therapy; estrogen
receptor; progesterone receptor; prospective cohort
Επίσημο URL (Εκδότης):
DOI:
10.1093/annonc/mdu150
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.